JP2020533295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533295A5 JP2020533295A5 JP2020513594A JP2020513594A JP2020533295A5 JP 2020533295 A5 JP2020533295 A5 JP 2020533295A5 JP 2020513594 A JP2020513594 A JP 2020513594A JP 2020513594 A JP2020513594 A JP 2020513594A JP 2020533295 A5 JP2020533295 A5 JP 2020533295A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mazindol
- substance
- treatment
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 7
- 229960000299 mazindol Drugs 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 4
- 208000011117 substance-related disease Diseases 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
- 229960002069 diamorphine Drugs 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229920003176 water-insoluble polymer Polymers 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555469P | 2017-09-07 | 2017-09-07 | |
| US62/555,469 | 2017-09-07 | ||
| PCT/IB2018/001138 WO2019058172A1 (en) | 2017-09-07 | 2018-09-06 | MAZINDOLE TREATMENT FOR HEROID DEPENDENCE AND DISORDER RELATED TO THE USE OF PSYCHOACTIVE SUBSTANCES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533295A JP2020533295A (ja) | 2020-11-19 |
| JP2020533295A5 true JP2020533295A5 (https=) | 2021-08-19 |
| JP7593619B2 JP7593619B2 (ja) | 2024-12-03 |
Family
ID=64316589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513594A Active JP7593619B2 (ja) | 2017-09-07 | 2018-09-06 | ヘロイン依存症及び物質使用障害のためのマジンドール治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11596622B2 (https=) |
| EP (1) | EP3678661A1 (https=) |
| JP (1) | JP7593619B2 (https=) |
| KR (1) | KR20200085730A (https=) |
| CN (1) | CN111343979A (https=) |
| BR (1) | BR112020004506A2 (https=) |
| CA (1) | CA3074054A1 (https=) |
| MX (1) | MX2020002560A (https=) |
| WO (1) | WO2019058172A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5217987A (en) | 1989-10-30 | 1993-06-08 | Berger Stephen P | Dopamine uptake inhibitors in reducing substance abuse and/or craving |
| US6323242B1 (en) | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| FR2899476B1 (fr) | 2006-04-11 | 2008-07-04 | Assist Publ Hopitaux De Paris | Association du mazindol dans le traitement du deficit de l'attention/hyperactivite |
| WO2009029308A1 (en) | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| JP2013523757A (ja) | 2010-03-31 | 2013-06-17 | スパーナス ファーマシューティカルズ インコーポレイテッド | マジンドールの製剤 |
| US9687445B2 (en) * | 2012-04-12 | 2017-06-27 | Lts Lohmann Therapie-Systeme Ag | Oral film containing opiate enteric-release beads |
| JP6584745B2 (ja) | 2014-04-09 | 2019-10-02 | 和久 前田 | 抗肥満薬の効果を向上させる組成物の製造方法。 |
| ES2884973T3 (es) | 2016-03-09 | 2021-12-13 | Nls Pharmaceutics Ag | Comprimido multicapa de mazindol de IR/SR y su utilización para el tratamiento del trastorno por déficit de atención/hiperactividad (ADHD) |
-
2018
- 2018-09-06 MX MX2020002560A patent/MX2020002560A/es unknown
- 2018-09-06 BR BR112020004506-3A patent/BR112020004506A2/pt not_active Application Discontinuation
- 2018-09-06 KR KR1020207009439A patent/KR20200085730A/ko not_active Ceased
- 2018-09-06 WO PCT/IB2018/001138 patent/WO2019058172A1/en not_active Ceased
- 2018-09-06 CN CN201880070488.1A patent/CN111343979A/zh active Pending
- 2018-09-06 US US16/645,306 patent/US11596622B2/en active Active
- 2018-09-06 JP JP2020513594A patent/JP7593619B2/ja active Active
- 2018-09-06 CA CA3074054A patent/CA3074054A1/en active Pending
- 2018-09-06 EP EP18803756.8A patent/EP3678661A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017057230A5 (https=) | ||
| CN103096881B (zh) | 含有具有不愉快味道的药物的膜制剂 | |
| RU2314810C2 (ru) | Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена | |
| JP2009525343A5 (https=) | ||
| JP2012533565A5 (https=) | ||
| MX2015011896A (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. | |
| JP2013511507A5 (https=) | ||
| JP2009536176A5 (https=) | ||
| JP2017506624A5 (https=) | ||
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| JP2011068653A5 (https=) | ||
| JP2010523587A5 (https=) | ||
| JP2015523407A5 (https=) | ||
| JP2005512995A5 (https=) | ||
| FI3710000T3 (fi) | Tradipitantti käytettäväksi gastropareesin hoidossa | |
| JP2015512406A5 (https=) | ||
| JP2014516942A5 (https=) | ||
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| JP2014518860A5 (https=) | ||
| JP2008543936A5 (https=) | ||
| JP2009280621A5 (https=) | ||
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| JP2018527305A5 (https=) | ||
| ME02474B (me) | Terapijski režimi |